STOCK TITAN

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Halozyme Therapeutics (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare Conference.

The presentation is scheduled for June 11, 2024, at 6:20 a.m. PT / 9:20 a.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Halozyme's website. Replays will be accessible for 90 days post-conference.

Positive
  • CEO Dr. Helen Torley will present at a prestigious event, potentially increasing investor interest.
  • Live audio webcast of the presentation ensures wider accessibility and transparency.
  • Replays available for 90 days offer extended opportunities for investor engagement.
Negative
  • No new financial or clinical data disclosed in the announcement.
  • Potentially impact on stock performance without significant news or updates.

SAN DIEGO, June 4, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare conference.

The presentation is scheduled for Tuesday, June 11 at 6:20 a.m. PT / 9:20 a.m. ET.

A live audio webcast will be available on the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com

Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-302163831.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When is Halozyme presenting at the Goldman Sachs 45th Annual Global Healthcare Conference?

Halozyme is scheduled to present on June 11, 2024, at 6:20 a.m. PT / 9:20 a.m. ET.

Who will represent Halozyme at the Goldman Sachs 45th Annual Global Healthcare Conference?

Dr. Helen Torley, president and CEO of Halozyme, will represent the company.

How can I access the live webcast of Halozyme's presentation?

The live audio webcast will be available on the Investor Relations section of Halozyme's website.

How long will the replay of the webcast be available?

Replays of the webcast will be available for 90 days following the conference.

Halozyme Therapeutics, Inc.

NASDAQ:HALO

HALO Rankings

HALO Latest News

HALO Stock Data

6.74B
127.27M
1.11%
99.2%
7.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO